Active — Not RecruitingNot Applicable

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

United States156 participantsStarted 2018-04-01

Plain-language summary

Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.

Who can participate

Age range17 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A diagnosis of first episode psychosis * Never been treated with an antipsychotic medication * Between the age of 17 and 35 Exclusion Criteria: * Inability to sign informed consent assessed by the Evaluation to sign - - Consent form * Poorly controlled acute or chronic medical and neurological conditions * History of head trauma with loss of consciousness for \>2 minutes * Clinically significant depression, hypomania, or mania * Active substance abuse or dependence (except for nicotine) * Suspected substance-induced psychosis * Treatment with drugs known to affect brain glutamate levels * Pregnant females

What they're measuring

Measures of brain structure

Timeframe: 32 weeks

Measures of brain function

Timeframe: 32 weeks

Measures of brain biochemistry

Timeframe: 32 weeks

Trial details

NCT IDNCT03442101

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-30

View on ClinicalTrials.gov More Psychosis trials